Navigation Links
aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
Date:8/14/2013

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- aTyr Pharma, an innovative disease therapeutics enterprise, announced today the expansion of the company's executive leadership team. Ms. Kelly Blackburn joins aTyr as vice president, Clinical Affairs. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a range of diseases. aTyr is advancing a therapeutic program to treat rare autoimmune diseases and a rare disease pipeline in immunology.

(Logo: http://photos.prnewswire.com/prnh/20120809/MM55538LOGO)

"At this key point in aTyr's evolution, the expansion of our executive leadership will help advance our first therapeutic program into the clinic in rare diseases," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. "Ms. Blackburn has more than 20 years of experience in managing and leading clinical programs, including the development of innovative molecules for rare diseases.  We look forward to Kelly's leadership as we work to rapidly translate our leading research in new Physiocrine biology into therapeutics for patients with grave immune diseases."

Ms. Blackburn was formerly the vice president, Clinical Development Operations at Vertex Pharmaceuticals where she was responsible for the operational plans and strategy for the full product portfolio including two transformational programs, KalydecoTM and Incivek®. Prior to Vertex, she was director, Clinical and Safety Operations at Millenium Pharmaceuticals, where she was operationally responsible for the lead product, VELCADE®.  Previous to that, she held several clinical operations roles of increasing responsibility at Vertex, Genetics Institute and Bayer Corporate. Ms. Blackburn received her B.S. in biochemistry from University of New Hampshire, MHA from Quinnipiac College and M.Ed. from Cambridge College.

About Physiocrines

Physiocrines act as extracellular signaling molecules to orchestrate cellular homeostasis in response to stress. Physiocrines are naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and the resolution of inflammation. As potent endogenous modulators of inflammation, Physiocrines offer the opportunity for modulating biological pathways through new naturally occurring mechanisms, many of which have multiple therapeutic advantages, including improved selectivity, efficacy and reduced side effect profiles compared to many existing anti-inflammatory therapeutics.

About aTyr Pharma

aTyr Pharma has developed an extensive pipeline of future therapeutic products based on Physiocrine biology. aTyr has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr's key programs are currently focused on rare immunomodulation disorders in the areas of inflammation and immunity. These diseases are serious potentially life threatening autoimmune conditions, for which there are currently no effective, safe, long term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
4. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
5. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
6. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
7. PipelineRx Announces Telepharmacy Contract with GNYHA Services
8. Emdeon Continues Focus on Patient-Centered Healthcare Solutions; Renews Chain Drug Consortium Contract for Multiple Pharmacy Solutions
9. ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
10. Valeant Pharmaceuticals Announces Continuance
11. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
Breaking Medicine News(10 mins):